Mesenchymal Stem Cell-Derived Nanovesicles as a Credible Agent for Therapy of Pulmonary Hypertension.
Sign Up to like & getrecommendations! Published in 2022 at "American journal of respiratory cell and molecular biology"
DOI: 10.1165/rcmb.2021-0415oc
Abstract: Extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) have been evaluated in many studies as promising therapeutic agents for pulmonary hypertension (PH). However, low yields and heterogeneity are a major barrier in the translational… read more here.
Keywords: msc nvs; pulmonary hypertension; derived nanovesicles; msc ... See more keywords
Stem Cell–derived Nanovesicles for the Treatment of Pulmonary Hypertension: Are We There Yet?
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Respiratory Cell and Molecular Biology"
DOI: 10.1165/rcmb.2022-0078ed
Abstract: Pulmonary arterial hypertension (PAH) is a progressive disease with highmortality rates and poor survival. The key pathophysiological feature of PAH is a hyperproliferation of resident pulmonary vascular cells resulting in inward remodeling of small pulmonary… read more here.
Keywords: msc nvs; cell; hypertension; vascular remodeling ... See more keywords